49 research outputs found
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
BACKGROUND
Blinatumomab, a bispecific monoclonal antibody construct that enables CD3-positive
T cells to recognize and eliminate CD19-positive acute lymphoblastic leukemia (ALL)
blasts, was approved for use in patients with relapsed or refractory B-cell precursor ALL
on the basis of single-group trials that showed efficacy and manageable toxic effects.
METHODS
In this multi-institutional phase 3 trial, we randomly assigned adults with heavily pretreated
B-cell precursor ALL, in a 2:1 ratio, to receive either blinatumomab or standardof-
care chemotherapy. The primary end point was overall survival.
RESULTS
Of the 405 patients who were randomly assigned to receive blinatumomab (271 patients)
or chemotherapy (134 patients), 376 patients received at least one dose. Overall survival was
significantly longer in the blinatumomab group than in the chemotherapy group. The
median overall survival was 7.7 months in the blinatumomab group and 4.0 months in the
chemotherapy group (hazard ratio for death with blinatumomab vs. chemotherapy, 0.71;
95% confidence interval [CI], 0.55 to 0.93; P = 0.01). Remission rates within 12 weeks after
treatment initiation were significantly higher in the blinatumomab group than in the chemotherapy
group, both with respect to complete remission with full hematologic recovery
(34% vs. 16%, P<0.001) and with respect to complete remission with full, partial, or incomplete
hematologic recovery (44% vs. 25%, P<0.001). Treatment with blinatumomab resulted
in a higher rate of event-free survival than that with chemotherapy (6-month estimates, 31%
vs. 12%; hazard ratio for an event of relapse after achieving a complete remission with full,
partial, or incomplete hematologic recovery, or death, 0.55; 95% CI, 0.43 to 0.71; P<0.001),
as well as a longer median duration of remission (7.3 vs. 4.6 months). A total of 24% of the
patients in each treatment group underwent allogeneic stem-cell transplantation. Adverse
events of grade 3 or higher were reported in 87% of the patients in the blinatumomab
group and in 92% of the patients in the chemotherapy group.
CONCLUSIONS
Treatment with blinatumomab resulted in significantly longer overall survival than chemotherapy
among adult patients with relapsed or refractory B-cell precursor ALL. (Funded
by Amgen; TOWER ClinicalTrials.gov number, NCT02013167.
Silencing of GATA3 defines a novel stem cell-like subgroup of ETP-ALL
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.This work was supported by a research grant from the Deutsche Krebshilfe (Mildred Scheel Professur) and the Wilhelm Sander-Stiftung to CD Baldu
Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning
The tyrosine kinase activity of the BCRâABL oncoprotein results in reduced apoptosis and thus prolongs survival of chronic myelogenous leukaemia cells. The tyrosine kinase inhibitor imatinib (formerly STI571) was reported to selectively suppress the proliferation of BCRâABL-positive cells. Assuming that imatinib could be included in pretransplantation conditioning therapies, we tested whether combinations of imatinib and Îł-irradiation or alkylating agents such as busulfan or treosulfan would display synergistic activity in BCRâABL-positive chronic myelogenous leukaemia BV173 and EM-3 cell lines. Further, primary cells of untreated chronic myelogenous leukaemia patients were assayed for colony forming ability under combination therapy with imatinib. Additionally, the cytotoxic effect of these combinations on BCRâABL-negative cells was investigated. In the cell lines a tetrazolium based MTT assay was used to quantify growth inhibition after exposure to cytotoxic drugs alone or to combinations with imatinib. Irradiation was applied prior to exposure to imatinib. Interaction of drugs was analysed using the median-effect method of Chou and Talalay. The combination index was calculated according to the classic isobologram equation. The combination imatinibâ+âÎł-irradiation proved to be significantly synergistic over a broad range of cell growth inhibition levels in both BCRâABL-positive cell lines and produced the strongest reduction in primary chronic myelogenous leukaemia colony-forming progenitor cells. Combinations of imatinibâ+âbusulfan and imatinibâ+âtreosulfan showed merely additive to antagonistic effects. Imatinib did not potentiate the effects of irradiation or cytotoxic agents in BCRâABL-negative cells. Our data provide the basis to further develop imatinib-containing conditioning therapies for stem cell transplantation in chronic myelogenous leukaemia
The European Hematology Association Roadmap for European Hematology Research: a consensus document
The European Hematology Association (EHA) Roadmap for European Hematology Research highlights major achievements in diagnosis and treatment of blood disorders and identifies the greatest unmet clinical and scientific needs in those areas to enable better funded, more focused European hematology research. Initiated by the EHA, around 300 experts contributed to the consensus document, which will help European policy makers, research funders, research organizations, researchers, and patient groups make better informed decisions on hematology research. It also aims to raise public awareness of the burden of blood disorders on European society, which purely in economic terms is estimated at âŹ23 billion per year, a level of cost that is not matched in current European hematology research funding. In recent decades, hematology research has improved our fundamental understanding of the biology of blood disorders, and has improved diagnostics and treatments, sometimes in revolutionary ways. This progress highlights the potential of focused basic research programs such as this EHA Roadmap.
The EHA Roadmap identifies nine âsectionsâ in hematology: normal hematopoiesis, malignant lymphoid and myeloid diseases, anemias and related diseases, platelet disorders, blood coagulation and hemostatic disorders, transfusion medicine, infections in hematology, and hematopoietic stem cell transplantation. These sections span 60 smaller groups of diseases or disorders.
The EHA Roadmap identifies priorities and needs across the field of hematology, including those to develop targeted therapies based on genomic profiling and chemical biology, to eradicate minimal residual malignant disease, and to develop cellular immunotherapies, combination treatments, gene therapies, hematopoietic stem cell treatments, and treatments that are better tolerated by elderly patients
Blood
The NUP214-ABL1 fusion gene in T-cell acute lymphoblastic leukemia (T-ALL) has recently been identified as a possible target for imatinib and related tyrosine kinase inhibitors, but exact data regarding the prognostic impact and frequency of the several putative NUP214-ABL1 mRNA transcripts are still missing. We investigated 279 adult patients with T-ALL treated within the framework of the GMALL 5/93 and 6/99 therapy trials for NUP214-ABL1 by using a novel multiplex real-time, quantitative polymerase chain reaction (PCR). Eleven (3.9%) patients were NUP214-ABL1 positive, and 5 different transcripts were observed; 8 patients had a thymic immunophenotype, 1 had an early T-cell immunophenotype, and 2 had a mature T-cell immunophenotype. NUP214-ABL1-positive and -negative patients did not differ significantly in their major clinical features. In contrast to previous reports suggesting an adverse clinical course for NUP214-ABL1-positive patients, no significant difference in overall survival was observed. Based on the results, we have established and tested a novel PCR method for simplified detection of the NUP214-ABL1 fusion gene
Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia
No abstract available